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ABSTRACT
Background: There is an unmet need for markers predicting the outcome of patients with advanced
soft tissue sarcoma (STS) treated with pazopanib. Since toxicity might be related to the anti-tumor
activity of the drug, the aim of this study was to determine whether pazopanib-induced proteinuria,
hypothyroidism and cardiotoxicity grade 3-4 were associated with outcome.
Methods: The combined results of the EORTC 62043 and 62072 trials were retrospectively assessed
and used in a landmark analysis to evaluate the effect of the toxicities on progression-free survival
(PFS) and overall survival (OS), using the Kaplan-Meier method and Cox regression models.
Results: Of the 333 eligible patients, 259 patients were included in the analyses, for which a landmark
time point of 60 days after randomization/registration was selected. Proteinuria occurred in 25.1%,
hypothyroidism in 22.0% and cardiotoxicity grade 3–4 in 5.8% of the patients (any grade in 41.7%).
There was no effect of the occurrence of proteinuria (6-months PFS 35.4% for patients with vs. 38.3%
for patients without proteinuria, HR 1.01, p¼ .953), hypothyroidism (41.2% vs. 36.5%, HR 0.82, p¼ .210)
or cardiotoxicity grade 3–4 (26.7% vs. 38.2%, HR 0.97, p¼ .897) on PFS. Nor was there an effect of pro-
teinuria (6-months OS 63.2% for patients with vs. 74.4% for patients without proteinuria, HR 1.22,
p¼ .196), hypothyroidism (76.2% vs. 70.5%, HR 0.75, p¼ .093) or cardiotoxicity grade 3–4 (80.0% vs.
77.2%, HR 0.93, p¼ .801) on OS.
Conclusion: There was no association between the occurrence of pazopanib-induced proteinuria,
hypothyroidism and cardiotoxicity and outcome. Therefore, these toxicities cannot be used as predic-
tors for pazopanib activity in patients with advanced STS.
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Introduction
Soft tissue sarcomas (STS) are a heterogeneous group of
tumors originating from mesenchymal tissue. These rare
tumors account for approximately 1% of all adult malignancies
and consist of over 50 different histological subtypes [1].
Cornerstone of the treatment of localized STS is surgery,
optionally preceded or followed by neoadjuvant/adjuvant
therapy, such as radiotherapy, systemic therapy and/or iso-
lated limb perfusion. Unfortunately, a considerable proportion
of patients present with locally advanced and/or metastatic
STS or will develop these stages over time. For these patients
only palliative treatment remains with median overall survival
times of 12–18 months [2–7]. First-line treatment usually con-
sists of doxorubicin, sometimes in combination with ifosfamide
for fit patients in need of a response [7]. Recently, the addition
of olaratumab to doxorubicin as first-line treatment was condi-
tionally approved, based on a randomized phase II study show-
ing a significant improvement in overall survival compared to
doxorubicin alone [8].
Up to the last decade, there were not many systemic
treatment options for patients failing to doxorubicin-based
first-line treatment, but in the past few years several other
agents have become available for patients with advanced
STS. One of these agents is pazopanib, an oral angiogenesis
tyrosine kinase inhibitor (TKI), targeting the vascular endo-
thelial growth factor receptor (VEGFR) and platelet derived
growth factor receptor (PDGFR). Based on an improvement
in progression-free survival (PFS) and an acceptable toxicity
profile, pazopanib was registered as second-line treatment
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for patients with advanced non-adipocytic STS after failure to
prior chemotherapy [9,10].
Although pazopanib yielded an almost three-fold prolonga-
tion of PFS over placebo, the observed response rates were
low (6–9%) and came at the expense of toxicities [9,10]. On the
other hand, there is also a subgroup of STS patients treated
with pazopanib with a long-term response (PFS  6 months,
36%) and long-term survival (OS  18 months, 34%), including
patients remaining progression-free for more than 2 years
(3.5%) [11]. These results illustrate the need for markers predict-
ing response and outcome at an early stage.
This unmet need for markers predicting response is
underlined by the observation that many patients in daily
clinical practice are worried about the effectivity of their
treatment, especially in the absence of any side-effects or
toxicity. The hypothesis that the occurrence of toxicity is
related to the anti-tumor activity of the drug, and that tox-
icity therefore can be used as a biomarker of efficacy has
been tested in multiple combinations of various types of
drugs and different types of cancer and for different toxic-
ities. Examples include the occurrence of sunitinib-induced
hypertension in renal cell carcinoma (RCC) [12,13] or gastro-
intestinal stromal tumors (GIST) [14,15], sorafenib-induced
diarrhea or hand-foot syndrome in hepatocellular cancer [16,
17], pazopanib or sunitinib-induced proteinuria in RCC [18],
and VEGF TKI-induced hypothyroidism in RCC [19]. In these
studies, the occurrence of VEGF TKI-induced toxicity was
associated with an improved response rate and/or survival.
Recently, also the occurrence of hematological toxicity in
patients with advanced STS treated with the classic chemo-
therapeutic agent doxorubicin was studied, but no associ-
ation between the severity of hematological toxicity and
response, progression-free survival or overall survival could
be demonstrated [20].
For the combination of pazopanib and advanced STS, one
of the most common toxicities of pazopanib, hypertension,
and its association with outcome has already been studied
[21]. In this study, pazopanib-induced hypertension was not
associated with outcome in STS patients treated with this
agent. However, what does not hold true for hypertension,
might be true for other pazopanib-specific toxicities. Therefore,
the aim of this study was to investigate whether the occur-
rence of three other common pazopanib-induced toxicities,
namely proteinuria, hypothyroidism and cardiotoxicity, follow-
ing treatment with pazopanib in patients with advanced STS,
was associated with outcome. Additionally, this study provides
more insight into the exact incidences of these pazopanib-spe-
cific toxicities in patients with advanced STS. These three toxic-
ities were chosen, because they are pazopanib-specific, most
likely not to affected/caused by the underlying disease, and
well registered during the study period.
Methods
Primary and secondary objectives
The primary objective of this study was to assess the poten-
tial association between three pazopanib-induced toxicities
and progression-free survival (PFS) of STS patients treated
with pazopanib: proteinuria, hypothyroidism and cardiotoxic-
ity related adverse events of grade 3–4. Secondary objectives
of this study were to assess the association between these
three pazopanib-induced toxicities and overall survival (OS)
of STS patients treated with pazopanib, and to describe
tumor and patient characteristics of the patients having these
toxicities. Additionally, the potential association between car-
diotoxicity of any grade and PFS and OS was assessed.
Patient population
The potential association between these pazopanib-induced
toxicities and outcome were assessed retrospectively in the
combined results of two prospectively performed studies of the
European Organisation for Research and Treatment of Cancer-
Soft Tissue and Bone Sarcoma Group (EORTC-STBSG): the phase
II EORTC 62043 trial [9] and the subsequent phase III EORTC
62072 trial [10]. Details of these studies are listed in supporting
information Table S1. All patients eligible for the 62043 trial
and 62072 trial who received pazopanib were included, except
for patients with liposarcoma. These patients were excluded
based on results of the phase II 62043 trial, where pazopanib
failed to demonstrate a sufficient beneficial effect in this STS
subtype. To investigate the potential impact of treatment with
pazopanib, all analyses for the three types of pazopanib-
induced toxicities were also performed on the patients in the
phase III 62072 trial receiving placebo.
Measurements of toxicity
Proteinuria was measured using the Urine Protein/Creatinine
(UPC) ratio and was defined as an UPC ratio greater than 45
mg/mmol, which is equivalent to an albumin/creatinine ratio
of greater than 30 mg/mmol. In both studies, urine creatin-
ine and protein levels were reported at baseline, at day 8 of
the first treatment period, at day 1 of each following treat-
ment period (28 days) and 28 days after the last treatment
administration. A patient was considered to have persistent
proteinuria when two of the UPC ratio measurements with
an interval of 1–2 weeks minimum exceeded the cutoff point
of 45 mg/mmol. Because the time period between two
sequential urinary samples was at least 2 weeks in both stud-
ies, patients with two consecutive positive tests were catego-
rized as having persistent proteinuria.
To determine the presence of hypothyroidism, thyroid
stimulating hormone (TSH) levels were measured and used
as a biomarker. Although there is no clear cutoff point, gen-
erally an upper normal limit between 2.5 mU/L and 4.0 mU/L
is used [22]. For the current study, a patient was considered
as having developed hypothyroidism if at least one TSH
value surpassed the threshold value of 4.0 mU/L. According
to the study protocols, the TSH levels were reported at base-
line and at 12 weeks in both studies. Thereafter, levels were
reported every 12 weeks (62043 trial) or 16 weeks (62072 trial).
Additionally, TSH levels were often measured in between, with
peaks around day 8, day 28 and day 56 (coinciding with the
times of UPC assessment and start of new treatment periods).
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Cardiotoxicity related adverse events were defined as
events which occurred after date of randomization/registra-
tion and were part of the following list: cardiac ischemia/
infarction, edema, hypertension, hypotension, supraventricu-
lar arrhythmia or extrasystole, or prolonged QTc interval.
Grading of the cardiotoxicity related adverse events was
determined according to the National Cancer Institute-
Common Terminology Criteria for Adverse Events version 3.0
(NCI-CTCAE v3.0) [23].
Statistical analyses
PFS was defined as time from date of registration/randomiza-
tion to the first documentation of progression or death, which-
ever occurred first. If no progression or death was observed,
patients were censored at the last date of follow-up. OS was
defined as time between date of registration/randomization
and date of death. Patients alive at time of clinical cutoff were
censored at the date of last follow-up.
To determine the appropriate landmark for further analy-
ses, the cumulative incidence of proteinuria, hypothyroidism
and cardiotoxicity related adverse events was assessed.
These landmark time points were used to assess the effect of
the pazopanib-induced toxicities on PFS and OS compared
to patients without toxicity, using the Kaplan Meier method
for univariate analyses and Cox regression models for multi-
variable analyses. The 6-months survival rates are calculated
taking the selected landmark as starting point (t = 0) and are
reported as percentages with their associated 95%
confidence intervals (95% CI). The multivariable models were
adjusted for other prognostic factors and included: perform-
ance status (0 or 1), gender (male or female), tumor grade
(low, intermediate or high), age at time of randomization
(50 years or >50 years) and histological subtype (leiomyo-
sarcoma, synovial sarcoma or other). In the multivariable
model for cardiotoxicity, cardiac history (yes or no) was also
included. For the multivariable analyses, an overview summa-
rizing the hazard ratios (HRs) with corresponding 95% CIs for
the three pazopanib-induced toxicities is presented.
Complete results including all covariates are shown in the
supplemental materials (supporting information Table S2–S9).
Two-sided tested p-values <.05 were considered statistically
significant. All statistical analyses were performed using SAS
version 9.4.
Results
Patient population
In total, 333 patients receiving pazopanib (118 out of the
62043 trial and 215 out of the 62072 trial) and 110 patients
receiving placebo met the eligibility criteria and were
included in the study (Figure 1). Of the 333 eligible patients
receiving pazopanib, 248 patients (74%) developed at least
one toxicity, of whom approximately one-third had just one
toxicity, 40% a combination of two toxicities and a quarter
of the patients all three toxicities. The remaining 85
patients (26%) did not experience any of the three toxicities
Figure 1. Flow chart illustrating the inclusion of patients out of the EORTC 62043 and 62072 trials in the current study.
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(supporting information Table S2). Assessment of the inci-
dence of the three toxicities showed that the majority of
patients who developed proteinuria, hypothyroidism or car-
diotoxicity (both of any grade and of grade 3–4) did so
within 60 days after registration/randomization (supporting
information Figure S1). Considering this time point as the
landmark for further analyses leaves a reasonable number
of patients at risk (N = 259).
Association between proteinuria and outcome
Overall, 65 of the 259 patients (25.1%) who received pazopa-
nib and who were included in the landmark analyses had
proteinuria at a certain point in time within the landmark
period of 60 days, of whom 22 patients had persistent pro-
teinuria (33.8% of the patients with proteinuria, 8.5% of the
total study population). These patients more often had a per-
formance score of 1 and a high grade tumor, were more
often female and >50 years of age than patients without
proteinuria (Table 1).
Univariate analysis showed no difference in PFS between
patients with proteinuria and patients without proteinuria
(Figure 2A), nor for patients with persistent proteinuria (sup-
porting information Figure S2A). After adjustment for other
prognostic factors, multivariable analysis also showed no sig-
nificant prognostic effect of proteinuria or persistent protein-
uria on PFS (Table 2). The presence of proteinuria or
persistent proteinuria also had no significant influence on OS
(Figure 2B and Table 2; supporting information Figure S2B).
Association between hypothyroidism and outcome
Approximately one-quarter of the patients developed hypo-
thyroidism within the landmark time point of 60 days (N =
57, 22.0%). These patients were slightly more often female
and aged 50 years and had slightly more often a perform-
ance score of 1 than patients without hypothyroidism
(Table 1).
There was no effect of the presence of hypothyroidism on
PFS (Figure 3A), also not after adjustment for other prognos-
tic factors (Table 2). Similarly, there was no significant prog-
nostic effect of the presence of hypothyroidism on OS
(Figure 3B), although an trend in favor of patients with hypo-
thyroidism was observed (Table 2).
Association between cardiotoxicity related adverse
events and outcome
In total, 108 patients (41.7%) experienced a cardiotoxicity
related adverse event of any grade within the landmark
period of 60 days, of whom 15 patients experienced grade
3–4 cardiotoxicity (13.9% of the patients with any grade car-
diotoxicity and 5.8% of the total study population). Three
patients experienced arrhythmia, one patient ischemia, but
the majority of patients had hypertension (N = 107). Notably,
Table 1. Baseline patient characteristics of patients with and without pazopanib-induced proteinuria, hypothyroidism or cardiotoxicity included in the landmark
analysis (i.e. patients who did not experience an event, progression or death, before the selected landmark time point of 60 days).
Proteinuria
Persistent
proteinuria Hypothyroidism
Cardiotoxicity
Grade 3–4
Cardiotoxicity
Any grade
Total
No Yes No Yes No Yes No Yes No Yes
(N¼ 194) (N¼ 65) (N¼ 237) (N¼ 22) (N¼ 202) (N¼ 57) (N¼ 244) (N¼ 15) (N¼ 151) (N¼ 108) (N¼ 259)
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Performance status
0 117 (60.3) 28 (43.1) 135 (57.0) 10 (45.5) 117 (57.9) 28 (49.1) 135 (55.3) 10 (66.7) 84 (55.6) 61 (56.5) 145 (56.0)
1 77 (39.7) 37 (56.9) 102 (43.0) 12 (54.5) 85 (42.1) 29 (50.9) 109 (44.7) 5 (33.3) 67 (44.4) 47 (43.5) 114 (44.0)
Type of regimen of advanced disease
One line of combination therapy 42 (21.6) 7 (10.8) 48 (20.3) 1 (4.5) 40 (19.8) 9 (15.8) 48 (19.7) 1 (6.7) 29 (19.2) 20 (18.5) 49 (18.9)
Two lines of single agent therapy 23 (11.9) 3 (4.6) 25 (10.5) 1 (4.5) 25 (12.4) 1 (1.8) 24 (9.8) 2 (13.3) 12 (7.9) 14 (13.0) 26 (10.0)
Missing 129 (66.5) 55 (84.6) 164 (69.2) 20 (90.9) 137 (67.8) 47 (82.5) 172 (70.5) 12 (80.0) 110 (72.8) 74 (68.5) 184 (71.0)
Sex
Male 79 (40.7) 24 (36.9) 95 (40.1) 8 (36.4) 84 (41.6) 19 (33.3) 98 (40.2) 5 (33.3) 59 (39.1) 44 (40.7) 103 (39.8)
Female 115 (59.3) 41 (63.1) 142 (59.9) 14 (63.6) 118 (58.4) 38 (66.7) 146 (59.8) 10 (66.7) 92 (60.9) 64 (59.3) 156 (60.2)
Tumor grade
Low 20 (10.3) 4 (6.2) 23 (9.7) 1 (4.5) 20 (9.9) 4 (7.0) 24 (9.8) 0 (0.0) 10 (6.6) 14 (13.0) 24 (9.3)
Intermediate 67 (34.5) 20 (30.8) 81 (34.2) 6 (27.3) 66 (32.7) 21 (36.8) 80 (32.8) 7 (46.7) 51 (33.8) 36 (33.3) 87 (33.6)
High 107 (55.2) 39 (60.0) 131 (55.3) 15 (68.2) 114 (56.4) 32 (56.1) 138 (56.6) 8 (53.3) 90 (59.6) 56 (51.9) 146 (56.4)
Missing 0 (0.0) 2 (3.1) 2 (0.8) 0 (0.0) 2 (1.0) 0 (0.0) 2 (0.8) 0 (0.0) 0 (0.0) 2 (1.9) 2 (0.8)
Histological subtype
Leiomyosarcoma 77 (39.7) 29 (44.6) 95 (40.1) 11 (50.0) 82 (40.6) 24 (42.1) 102 (41.8) 4 (26.7) 59 (39.1) 47 (43.5) 106 (40.9)
Synovial sarcoma 41 (21.1) 10 (15.4) 48 (20.3) 3 (13.6) 42 (20.8) 9 (15.8) 46 (18.9) 5 (33.3) 32 (21.2) 19 (17.6) 51 (19.7)
Other 76 (39.2) 26 (40.0) 94 (39.7) 8 (36.4) 78 (38.6) 24 (42.1) 96 (39.3) 6 (40.0) 60 (39.7) 42 (38.9) 102 (39.4)
Age at randomization
50 87 (44.8) 15 (23.1) 98 (41.4) 4 (18.2) 76 (37.6) 26 (45.6) 96 (39.3) 6 (40.0) 69 (45.7) 33 (30.6) 102 (39.4)
>50 107 (55.2) 50 (76.9) 139 (58.6) 18 (81.8) 126 (62.4) 31 (54.4) 148 (60.7) 9 (60.0) 82 (54.3) 75 (69.4) 157 (60.6)
Cardiac history
No 188 (77.0) 8 (53.3) 116 (76.8) 80 (74.1) 196 (75.7)
Yes 56 (23.0) 7 (46.7) 35 (23.2) 28 (25.9) 63 (24.3)
Type of cardiotoxicity
Arrhythmia 259 (100.0) 0 (0.0) 256 (98.8) 3 (1.2) 3 (1.2)
Hypertension 244 (94.2) 15 (5.8) 152 (58.7) 107(41.3) 107 (41.3)
Ischemia 259 (100.0) 0 (0.0) 258 (99.6) 1 (0.4) 1 (0.4)
Multiple cardiotoxicities per patient can occur, and are in that case counted multiple times for in this table.
ACTA ONCOLOGICA 875
Figure 2. Kaplan-Meier curves showing the progression-free survival (A) and overall survival (B) of patients with and without pazopanib-induced proteinuria.
Table 2. Overview of the effect of the three pazopanib-induced toxicities on PFS and OS in patients receiving pazopanib
at landmark time point of 60 days, univariate (6-months PFS/OS rates) and multivariable after adjustment for other prog-
nostic factors in multivariable Cox regression analysis. The reported p-values belong to the multivariable Cox regression
model. Results of the complete Cox regression analyses are shown in supplemental tables S3–S10.
Progression-free survival Overall survival
6m PFS (95% CI) HR (95% CI) p-value 6m OS (95% CI) HR (95% CI) p-value
Proteinuria
No 38.3% (31.4–45.1) 1
.953
74.4% (68.3–79.5) 1
.196Yes 35.4% (24.0–46.9) 1.01 (0.75, 1.36) 63.2% (51.3–72.9) 1.22 (0.90, 1.64)
Persistent proteinuria
No 37.7% (31.5–43.8) 1
.937
73.3% (67.7–78.0) 1
.169Yes 36.4% (17.4–55.7) 0.98 (0.62, 1.55) 53.9% (33.3–70.6) 1.38 (0.87, 2.19)
Hypothyroidism
No 36.5% (29.9–43.2) 1
.210
70.5% (64.3–75.7) 1
.093Yes 41.2% (28.3–53.6) 0.82 (0.61, 1.12) 76.2% (63.7–84.9) 0.75 (0.54, 1.05)
Cardiotoxicity grade 3–4
No 38.2% (32.1–44.3) 1
.897
77.2% (71.4–82.0) 1
.801Yes 26.7% (8.3–49.6) 0.97 (0.57, 1.64) 80.0% (50.0–93.1) 0.93 (0.52, 1.65)
Cardiotoxicity any grade
No 40.6% (32.7–48.3) 1
.380
75.9% (68.1–82.0) 1
.120Yes 33.3% (24.7–42.2) 1.12 (0.87, 1.46) 79.5% (70.5–86.0) 0.81 (0.63, 1.06)
6m PFS: 6-months progression-free survival; 6m OS: 6-months overall survival; 95% CI: 95% confidence interval; HR: haz-
ard ratio.
Figure 3. Kaplan-Meier curves showing the progression-free survival (A) and overall survival (B) of patients with and without pazopanib-induced hypothyroidism.
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the number of patients experiencing cardiotoxicity other
than hypertension was too low to perform separate reliable
analyses on. Most of the patients experiencing cardiotoxicity
had a performance score of 0, were female, over 50 years old
and had intermediate or high-grade tumors. Patients with car-
diotoxicity grade 3–4 more often had a cardiac history (46.7%)
compared to patients without toxicity (23.0%) and patients
with cardiotoxicity of any grade (25.9%) (Table 1).
Univariate analysis showed no difference in PFS between
patients with and without cardiotoxicity related adverse
events grade 3–4 (Figure 4A). Also in multivariable analysis,
after adjustment for other prognostic factors, no significant
effect of the occurrence of cardiotoxicity related adverse
events grade 3–4 on PFS was observed (Table 2). Likewise,
cardiotoxicity of any grade was not of significant influence
(Table 2, supporting information Figure S3A). Additionally,
there was no association between the occurrence of cardio-
toxicity grade 3–4 and OS (Figure 4B), nor in multivariable
analysis (Table 2). There was also no association between the
occurrence of cardiotoxicity of any grade and OS (Table 2,
supporting information Figure S3B).
Association between toxicity and outcome in patients
receiving placebo
For all three pazopanib-induced toxicities, the analyses were
also performed on the patients receiving placebo in the
62072 trial. However, no effect on PFS or OS was observed
for any of the toxicities in patients receiving placebo (sup-
porting information Tables S5, S7 and S10).
Discussion
The association between three pazopanib-induced toxicities
and outcome of patients with advanced STS has been inves-
tigated in this study. We observed that pazopanib-induced
proteinuria occurred in 25.1% of the patients treated with
pazopanib within 60 days after start of treatment, of whom
8.5% had persistent proteinuria. Hypothyroidism was
observed in 22.0% of the patients while on treatment with
pazopanib. At last, cardiotoxicity (any grade) occurred in
41.7% of patients on treatment, of whom 5.8% had grade
3–4 cardiotoxicity. Additionally, we observed that cardiotoxic-
ity other than hypertension only occurred occasionally in 1.5%
of the patients and was only of grade 1 or 2. Overall, no sig-
nificant prognostic effects were observed for one of these
three pazopanib-induced toxicities on PFS or OS. However,
although not significant, a trend towards a better prognosis
for patients developing hypothyroidism (i.e. high TSH levels)
within 60 days after start of pazopanib was observed.
The incidences of the three pazopanib-induced toxicities
observed in this study differ slightly from incidences
observed in patients with RCC treated with pazopanib. The
incidences of proteinuria (25.1%) and hypothyroidism (22.0%)
observed in this study were higher than observed for RCC
patients. For proteinuria, incidences of 14–18% for patients
with RCC have been reported [18,24,25]. Importantly, the
majority of these patients underwent a prior nephrectomy,
which might have affected the onset of proteinuria.
Hypothyroidism was observed in <10%–18% of RCC patients
treated with pazopanib [24–26], but to the best of our know-
ledge, no clear explanation for the differences in incidence
of hypothyroidism between patients with RCC and patients
with STS exists. On the contrary, the incidence of any grade
cardiotoxicity (including hypertension) was slightly lower
than observed in RCC patients, varying from 42 to 69%,
although definitions of cardiotoxicity differed among RCC
studies [24,25,27,28]. Comparable to STS patients treated with
pazopanib, the majority of the RCC patients with cardiotoxicity
had hypertension, and only a small proportion had myocardial
ischemia/infarction or QTc prolongation. Inhibiting the VEGF
signaling pathway itself can already induce cardiotoxicity
because of its working mechanism [29], but other aspects,
such as preceding cancer therapy (anthracyclines), preexisting
hypertension or other cardiac history, may also play a role in
inducing/worsening cardiotoxicity [30]. Even though most STS
patients had received doxorubicin as first-line treatment,
which is known for its cumulative cardiotoxicity, the incidence
Figure 4. Kaplan-Meier curves showing the progression-free survival (A) and overall survival (B) of patients receiving pazopanib with and without pazopanib-
induced cardiotoxicity of grade 3–4.
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of pazopanib-induced cardiotoxicity was not higher than was
described in patients with RCC.
Depending on the severity of toxicity, actions were taken
according to protocols. In case of proteinuria, pazopanib was
interrupted until the UPC ratio had recovered and pazopanib
was restarted at a lower dose. For patients developing hypo-
thyroidism, thyroid replacement therapy was started. At last,
in case of cardiotoxicity grade 3–4, pazopanib was discontin-
ued and the cardiotoxicity was treated, whereas for grade 1–2
cardiotoxicity, pazopanib could be continued at the current
dose or restarted at a lower dose while treating the
cardiotoxicity.
In line with the study on the association between pazopa-
nib-induced hypertension and outcome [21], we did not
observe a significant prognostic effect of pazopanib-induced
proteinuria, hypothyroidism or cardiotoxicity in patients with
advanced STS. This is in contrast to studies examining toxic-
ities induced by anti-VEGF treatment in other types of can-
cer, such as RCC, hepatocellular cancer, colorectal cancer and
GIST. In these studies, a significant association between suni-
tinib or pazopanib-induced proteinuria and OS was observed
in RCC patients [18], and bevacizumab-induced proteinuria
was associated with response rate in patients with metastatic
colorectal cancer [31]. Additionally, RCC patients with suniti-
nib-induced or sorafenib-induced hypothyroidism showed
increased response rates [32], improved PFS [19,33] and
improved OS [19,32]. Furthermore, the occurrence of other
sunitinib-induced or sorafenib-induced toxicities, such as
hypertension, skin toxicity and diarrhea, was significantly asso-
ciated with an increase in response rate [12–14], improved
PFS [12,14,15] and improved OS [12,14–17,34,35]. To the best
of our knowledge, no studies have been published regarding
anti-VEGF therapy-induced cardiotoxicity and its association
with outcome, except for hypertension.
The thresholds used to determine toxicity, especially for
hypothyroidism, and the choice of the landmark time points
might be considered as an arbitrary choice to some extent.
Whereas the NCI-CTCAE and UPC ratio are well known and
established methods to determine and document cardiotox-
icity and proteinuria, no clear TSH cutoff point for the diag-
nosis of hypothyroidism has been agreed upon. Normal
ranges of TSH levels may vary by individual, over the day,
and even among laboratories, but generally an upper normal
limit between 2.5 mU/L and 4.0 mU/L is used [22]. Hence,
the TSH threshold value of 4.0 mU/L used in this study is
relatively high and conservative, but allowed us to identify
each case of hypothyroidism with more certainty, while still
a reasonable number of patients were at risk in both groups.
Although the data included in this study were collected
prospectively in the two EORTC trials, there are still some
potential sources of bias and limitations related to the retro-
spective design of this study. There were some small differ-
ences in, for example, patient and disease characteristics
between the two study populations, as well as small differen-
ces in the follow-up schedules and in the definition of PFS in
the two studies, which might have influenced the outcome.
Furthermore, time-to-event bias might have an impact, a
type of bias where patients with a favorable response to
pazopanib are more likely to continue treatment for a longer
period of time, and the longer the exposure to the agent,
the higher the chance of developing toxicity. To avoid this
potential source of bias, a landmark analysis was used.
To investigate the potential association of the occurrence
of toxicity and outcome following treatment with pazopanib,
all analyses for the three types of toxicities have been per-
formed on patients receiving the drug as well as on the
patients in the phase III trial receiving placebo. As only a few
of the patients receiving placebo did not experience progres-
sion/death before the landmark time point of 60 days and
even a lower number of toxicities was observed in this
patient group, unfortunately no real comparison could be
made and no clear conclusions on a potential placebo-effect
could be drawn.
The hypothesis that the occurrence of toxicity is related
to efficacy of the drug and therefore outcome, prevails not
only amongst physicians, but also amongst patients. Some
patients in daily clinical practice are concerned whether their
treatment with pazopanib is effective if they do not experi-
ence any side-effects or toxicity. The results of this study
may provide reassurance to the treating physicians as well as
these patients that the absence of toxicity does not imply
that there will be no benefit of treatment with pazopanib.
Conclusion
The occurrence of pazopanib-induced proteinuria, hypothy-
roidism or cardiotoxicity in patients with advanced STS
treated with pazopanib did not have a significant predictive
effect and was not associated with outcome. These toxicities
can therefore not be used as predictor for pazopanib activity
in these patients.
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